Nanobiotix Announces Positive Preclinical AACR Data for Nanoprimer Technology in LNP-DNA Delivery

Nanobiotix S.A. (NASDAQ: NBTX) announced new preclinical data for its Nanoprimer technology at the 2026 Annual Meeting of the American Association for Cancer Research (AACR). The study, conducted in collaboration with Earli, evaluated the Nanoprimer platform in sequence with lipid nanoparticle-delivered recombinant DNA (LNP-DNA) in mouse models. The Nanoprimer is designed to transiently occupy hepatic clearance pathways to overcome the rapid liver uptake that typically limits LNP-delivered therapies. Key observations from the study showed that pre-treatment with Nanoprimer followed by intravenous administration of LNP-DNA resulted in increased systemic bioavailability, reduced hepatic exposure and toxicity, and a mitigation of the inflammatory response by attenuating the cGAS-STING pathway. These results support the potential of Nanoprimer to optimize advanced delivery systems for extrahepatic delivery. Management indicated that they are pursuing a dual-path development strategy involving both internal proprietary pipelines and external collaborations with partners facing liver accumulation challenges.